Passport Health

Thirty million Americans travel internationally each year, and the majority of them are dangerously underprepared for the health risks waiting at their destination. Typhoid fever, yellow fever, hepatitis A, meningococcal disease, and a rotating cast of region-specific threats require specialized clinical knowledge and vaccine access that a standard primary care physician's office rarely provides. That gap between the demand for expert travel medicine and its consistent availability is precisely the problem Passport Health was built to solve. Founded in 1994 by Fran Lessans in Baltimore, Maryland, Passport Health opened its first clinic with a clear and differentiated thesis: travel medicine deserved its own dedicated infrastructure, staffed by specialists, stocked with the right vaccines, and positioned to serve travelers efficiently before departure. Lessans, who continues to serve as Founder and CEO, built a model that resonated immediately, and the company expanded from that single Baltimore location to 34 offices across 15 U.S. states by the year 2000, just six years after opening. Today, the company's corporate headquarters is located in Scottsdale, Arizona, and the network has grown to over 280 clinics across North America, with international locations now operating in the United Kingdom following the 2019 expansion into London, England. The brand's Canadian presence dates to 2013, when clinics first opened in Toronto, with Mexico City following shortly thereafter, making Passport Health one of the very few travel medicine franchise systems with a genuine multinational footprint. For franchise investors evaluating the healthcare services sector, Passport Health represents a niche-dominant, recurring-demand brand operating within the global Physicians and Other Health Practitioners market, a category that generated approximately $1,430.20 billion in revenue in 2020 and is projected to reach $2,010.24 billion by the end of 2027. This is not a promotional summary; this is independent analysis of a franchise opportunity that has now operated for over three decades and navigated significant corporate transition, and it demands careful, data-driven scrutiny.

The broader healthcare services industry context for the Passport Health franchise opportunity is defined by scale and structural growth that would be difficult to manufacture artificially. The global Physicians and Other Health Practitioners market, within which Passport Health operates as a specialty sub-segment, was valued at an estimated $1,852.04 billion in 2025 and is projected to expand to $1,950.82 billion in 2026 alone, representing a compound annual growth rate of 5.3% in the near term and 8.7% over the 2021 to 2027 forecast period. North America was the dominant geographic region in 2020, commanding 47% of the global market share, and maintained that position through 2025. Within the United States specifically, the physician groups market was estimated at $349.49 billion in 2024 and is projected to grow at a CAGR of 7.62% from 2025 through 2030. Consumer trends reinforcing the travel medicine segment specifically include rising international travel volumes, a growing awareness of vaccine-preventable disease risk among leisure and business travelers, and the expansion of employer-driven occupational health programs that require specialized immunization services. Passport Health has strategically diversified its service mix to capture multiple revenue streams within this environment, expanding beyond travel vaccines to include onsite vaccination events, specialty physical exams, wellness services, and vaccine records management services, making the brand relevant to corporate clients, not just individual travelers. The company has established itself as one of the largest onsite flu clinic providers in the United States, delivering influenza vaccines to hundreds of thousands of employees from Fortune 500 corporations and small businesses across all 50 states, a market position that provides substantial revenue diversification from any single service line. From a competitive dynamics perspective, the travel medicine space remains fragmented at the local level but is consolidating at the national level, and Passport Health's scale, pharmaceutical purchasing agreements, and brand recognition create meaningful barriers to entry for independent operators.

Understanding the Passport Health franchise cost structure requires examining multiple data layers, because the investment figures reported across sources reflect meaningful variation depending on the format, location, and time period of the disclosure. The franchise fee has been reported in a range from $15,000 to $35,000 across different FDD cycles, with the most commonly cited figures being $25,000 to $35,000 for a standard market entry. The total initial investment range is similarly variable: one data set places it between $75,950 and $106,400, another between $63,550 and $166,500, and a third lower-cost scenario at $29,500 to $69,500, reflecting the capital efficiency possible in a service-based medical franchise that does not require significant build-out or manufacturing infrastructure. By comparison to broader franchise category averages, a total initial investment under $170,000 positions Passport Health as an accessible to mid-tier franchise investment relative to the healthcare services segment, where multi-site clinic concepts frequently require $250,000 or more in total capitalization. The ongoing royalty rate is 7%, which sits at the upper end of typical healthcare franchise royalty structures but is partially offset by the purchasing power advantages negotiated directly with pharmaceutical suppliers on behalf of franchisees. The maximum advertising fee is 2.0%, bringing the total ongoing fee load to approximately 9.0% of gross revenue, which franchise investors should model carefully when constructing unit economics scenarios. Working capital requirements are specified at $15,000 to $25,000, net worth requirements are set at $76,000, and liquid capital requirements of $50,000 represent the most commonly cited minimum, though some sources note a lower threshold of $15,000 in minimum cash. The initial franchise agreement term runs five years, which is shorter than the 10-year terms common in food and retail franchise systems and reflects the leaner contractual structure typical of service-based healthcare models. Prospective franchisees should consult with an SBA-qualified lender about financing eligibility, as healthcare service franchises with established brand histories frequently qualify for SBA-backed loan programs.

The daily operating reality of a Passport Health franchise is structured around a clinical service model that is simultaneously specialized and operationally streamlined. Each clinic is staffed by licensed healthcare professionals, typically registered nurses or nurse practitioners, who conduct pre-travel consultations, administer vaccines, dispense travel health supplies, and maintain vaccine records for clients traveling to high-risk destinations. The franchise model is designed to function as a low-overhead service business, with no significant inventory carrying costs, no food service complexity, and no heavy capital equipment requirements beyond standard medical and refrigeration supplies. The initial training program runs approximately two weeks, combining in-person instruction at Passport Health's corporate facility with digital learning resources, covering clinical protocols, client consultation frameworks, compliance requirements, scheduling systems, and business development strategies. Ongoing operational support includes access to a library of marketing and administrative tools, field support from corporate operations consultants, and the benefit of Passport Health's negotiated pharmaceutical discounts, which allow franchisees to purchase vaccines at rates not accessible to independent operators. The system also provides private label products and services under the Passport Health brand, offering franchisees incremental revenue opportunities with the credibility of instant name recognition built over three decades. Territory structures suggest that the brand is actively expanding into new domestic and international markets, with the South representing the largest regional concentration at 73 locations across 26 states plus the District of Columbia as of the 2016 FDD. Corporate guidance positions the Passport Health franchise as suitable for both owner-operators with clinical backgrounds and entrepreneurs who hire qualified healthcare staff, with the "simple, low-overhead service company" descriptor suggesting an absentee-capable model for experienced multi-unit operators, though specific policy on absentee ownership should be confirmed directly with the franchisor during the discovery process.

Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document for the Passport Health franchise. This is a significant consideration for prospective investors, because the FTC does not require franchisors to disclose earnings claims in Item 19, but when franchisors choose not to, investors must construct their own financial models from publicly available data and industry benchmarks. The absence of Item 19 disclosure is not unique to Passport Health, as a substantial proportion of franchise systems across all categories decline to provide earnings claims, but it does increase the due diligence burden on the investor and underscores the importance of speaking with existing franchisees under Item 20 of the FDD to gather real-world revenue and cost data. What can be triangulated from the available public record is that the Passport Health system generated sufficient unit-level economics to support a network that grew from 1 location in 1994 to 34 by the year 2000, to over 300 by 2014, and to 280 clinics across North America by 2019, a growth arc that reflects sustained franchisee demand for the model. The brand's corporate development record includes the acquisition of Mollen Immunizations on January 1, 2012, and Medichecks on January 1, 2002, both of which expanded the network's capacity and service capabilities and suggest that unit-level returns were sufficient to attract capital for strategic consolidation. Passport Health was itself acquired on April 1, 2023, a transaction that introduces both opportunity and uncertainty into the investment thesis, as acquisition events in franchise systems can bring operational improvements and capital investment but can also introduce cultural disruption, as some franchisee reviews from late 2025 have noted regarding post-acquisition management changes. Investors should benchmark individual clinic revenue potential against the travel medicine industry's patient volume data, the company's self-reported status as a flu vaccine provider to hundreds of thousands of employees annually, and the working capital floor of $15,000 to $25,000 which implies relatively modest ongoing cash burn for stabilized locations.

The Passport Health franchise growth trajectory over its thirty-year history is one of the more compelling expansion stories in the specialty healthcare franchise segment, though the trajectory has not been linear and requires careful interpretation. The network's peak of over 300 locations documented in 2014 contracted to approximately 175 franchised locations in the U.S. by the 2016 FDD filing period, and then recovered to approximately 280 clinics across North America by 2019, a pattern that may reflect natural churn in the franchise system, the integration of acquired networks, or market corrections following overexpansion. The 2013 launch in Toronto, Canada, the 2014 confirmed opening of Mexico City, Mexico locations, and the 2019 entry into London, England under Chairman David Tedesco's international expansion strategy represent genuine competitive differentiation, as very few travel medicine franchise systems have successfully built an international network. The company's competitive moat is constructed from several durable elements: three decades of brand recognition in a trust-intensive medical services category, pharmaceutical purchasing agreements that reduce a franchisee's cost of goods, proprietary private-label products not available to independent operators, and a national infrastructure that enables Fortune 500 corporate flu clinic contracts which individual clinics could not win independently. Passport Health's 2001 collaboration with the Centers for Disease Control and Prevention to administer antibiotics and vaccines to postal and tabloid workers following the Anthrax attacks is a historical proof point of the brand's clinical credibility and government trust relationships. The corporate acquisition in April 2023 has introduced new leadership dynamics, and franchisee feedback from November and December 2025 includes some concerns about post-acquisition culture shifts, pressure to prioritize vaccine sales volume, and training disorganization following the transition, all of which represent material due diligence flags that prospective investors should investigate directly with existing franchisees and the franchisor.

The ideal Passport Health franchisee combines an entrepreneurial disposition with comfort operating in a regulated healthcare environment. Clinical professionals, including registered nurses, pharmacists, and nurse practitioners who wish to transition into business ownership, represent a natural fit because the service model centers on licensed healthcare delivery that requires clinical credibility with clients. However, the franchise model also accommodates business-oriented entrepreneurs without clinical backgrounds who hire qualified clinical staff, particularly in larger markets where patient volume can support a full-time medical professional on payroll. Multi-unit operation is a viable strategy within the Passport Health system given the standardized clinic model and the relative consistency of the service offering across markets, though the 5-year initial agreement term is shorter than typical multi-unit development timelines and renewal terms should be evaluated carefully. Available territories exist in domestic U.S. markets as well as internationally, with the brand continuing to seek new franchisees across North America and in the United Kingdom, where the 2019 London entry established the operational framework for continued European expansion. Markets with high concentrations of international business travelers, academic medical centers, and Fortune 500 corporate campuses historically represent the strongest demand environments for travel medicine services. Prospective owners with healthcare administration experience, corporate wellness sales backgrounds, or existing relationships with occupational health clients bring measurable advantages to the business development side of clinic operations. The franchise agreement's 5-year initial term, combined with working capital requirements of $15,000 to $25,000 and a net worth minimum of $76,000, creates a relatively accessible barrier to entry for healthcare-adjacent professionals seeking to own a specialized medical practice with franchisor support infrastructure.

The investment thesis for the Passport Health franchise opportunity sits at the intersection of a durable secular trend and a specialized service that is structurally difficult to commoditize. International travel volumes are growing, the regulatory complexity around travel vaccinations is increasing, and employer-driven occupational health spending continues to expand, all of which create persistent demand for exactly the specialized, expert-guided vaccination services that Passport Health has delivered since 1994. The absence of Item 19 financial performance disclosure and the concerns documented in post-2023 acquisition franchisee reviews are meaningful considerations that elevate the due diligence standard required before signing an agreement, and no investor should proceed without conducting thorough conversations with existing franchisees, reviewing the full current FDD with a qualified franchise attorney, and modeling unit economics against local market demand data. The Franchise Performance Index score of 44, rated as Fair by independent analysis, reflects the complexity of this evaluation and underscores that while the brand's history and market position are genuine strengths, the current system has characteristics that warrant careful scrutiny rather than straightforward endorsement. PeerSense provides exclusive due diligence data including SBA lending history, FPI score analysis, location maps with verified Google ratings, FDD financial data across multiple disclosure years, and side-by-side comparison tools that allow investors to benchmark the Passport Health franchise cost and performance profile against competing concepts within the healthcare services and travel medicine franchise categories. Explore the complete Passport Health franchise profile on PeerSense to access the full suite of independent franchise intelligence data and make the most informed capital allocation decision possible.